NCT07053891Recruiting
LUPKYNIS Drug-use Results Survey
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 27 Jun 2025
- Start date
- 17 Sept 2025
- Primary completion date
- 30 Jun 2031
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Diseases
- Lupus (SLE)
- NCT number
- NCT07053891
What you commit to
- Study type: Observational
- Planned participants: 400
- From 17 Sept 2025 to the primary completion date, 30 Jun 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Patients who are newly starting administration of LUPKYNIS for lupus nephritis
Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmacovigilance Department Coordinator of this site? Confirm its status | Osaka | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.